Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 661 | 65 | 584 |
| Samples | 178 | 28 | 147 |
| Peptides | 151 | 19 | 132 |
Function
CYTH1 · Cytohesin 1
The protein encoded by this gene is a member of the PSCD family. Members of this family have identical structural organization that consists of an N-terminal coiled-coil motif, a central Sec7 domain, and a C-terminal pleckstrin homology (PH) domain. The coiled-coil motif is involved in homodimerization, the Sec7 domain contains guanine-nucleotide exchange protein activity, and the PH domain interacts with phospholipids and is responsible for association of PSCDs with membranes. Members of this family appear to mediate the regulation of protein sorting and membrane trafficking. This gene is highly expressed in natural killer and peripheral T cells, and regulates the adhesiveness of integrins at the plasma membrane of lymphocytes. A pseudogene of this gene has been defined on the X chromosome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2014].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 139 amino-acid changes on canonical ENST00000446868 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CYTH1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CYTH1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Endometrial Carcinoma | 0/42 0% | 8/612 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Colorectal Carcinoma | 4/143 3% | 28/3239 1% |
| Melanoma | 4/210 2% | 14/1899 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 8/1390 1% |
| Bladder Carcinoma | 0/58 0% | 6/956 1% |
| Neuroendocrine Tumour | 3/154 2% | 1/577 0% |
| Gastric Carcinoma | 1/74 1% | 9/1809 0% |
| Other Solid Cancers | 1/94 1% | 7/1515 0% |
| Biliary Tract Carcinoma | 0/54 0% | 5/950 1% |
| Hepatocellular Carcinoma | 0/46 0% | 11/2210 0% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 3/810 0% |
| Glioma | 0/52 0% | 7/2127 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Ovarian Carcinoma | 1/109 1% | 2/998 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 3/1592 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Breast Carcinoma | 3/144 2% | 4/3264 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 5/2550 0% |
| Prostate Carcinoma | 0/13 0% | 4/2105 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 3/2534 0% |
| Neuroblastoma | 1/87 1% | 1/1331 0% |
| Other Blood Cancers | 0/61 0% | 2/2725 0% |
| Pancreatic Carcinoma | 1/89 1% | 0/1611 0% |
Mutation Distribution
Where CYTH1 is mutated · all tissues, split by cell line vs tissue
How many mutations in CYTH1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 661 mutations in CYTH1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|